MX365886B - Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. - Google Patents

Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.

Info

Publication number
MX365886B
MX365886B MX2017007448A MX2017007448A MX365886B MX 365886 B MX365886 B MX 365886B MX 2017007448 A MX2017007448 A MX 2017007448A MX 2017007448 A MX2017007448 A MX 2017007448A MX 365886 B MX365886 B MX 365886B
Authority
MX
Mexico
Prior art keywords
combination
chronic
epigentic
nutra
diabetis
Prior art date
Application number
MX2017007448A
Other languages
English (en)
Spanish (es)
Other versions
MX2017007448A (es
Inventor
Astudillo De La Vega Horacio
Original Assignee
Astudillo De La Vega Horacio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astudillo De La Vega Horacio filed Critical Astudillo De La Vega Horacio
Priority to RU2018147077A priority Critical patent/RU2749950C2/ru
Priority to BR112018075395-5A priority patent/BR112018075395A2/pt
Priority to EP17810608.4A priority patent/EP3470060B1/en
Priority to CA3027048A priority patent/CA3027048A1/en
Priority to JP2019517750A priority patent/JP2019521184A/ja
Priority to CN201780046806.6A priority patent/CN109890369B/zh
Priority to ES17810608T priority patent/ES2988151T3/es
Priority to PCT/MX2017/000061 priority patent/WO2017213486A2/es
Publication of MX2017007448A publication Critical patent/MX2017007448A/es
Priority to CL2018003531A priority patent/CL2018003531A1/es
Publication of MX365886B publication Critical patent/MX365886B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2017007448A 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. MX365886B (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU2018147077A RU2749950C2 (ru) 2015-06-08 2017-06-08 Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека
BR112018075395-5A BR112018075395A2 (pt) 2015-06-08 2017-06-08 combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas
EP17810608.4A EP3470060B1 (en) 2016-06-08 2017-06-08 Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
CA3027048A CA3027048A1 (en) 2015-06-08 2017-06-08 Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes
JP2019517750A JP2019521184A (ja) 2015-06-08 2017-06-08 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物
CN201780046806.6A CN109890369B (zh) 2015-06-08 2017-06-08 用于预防和减轻由糖尿病引起的慢性损伤的严重性的代谢调节剂和化合物的组合
ES17810608T ES2988151T3 (es) 2015-06-08 2017-06-08 Composición que comprende resveratrol, glicina, arginina y cisteína para su uso en el tratamiento del síndrome metabólico
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas
CL2018003531A CL2018003531A1 (es) 2016-06-08 2018-12-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases

Publications (2)

Publication Number Publication Date
MX2017007448A MX2017007448A (es) 2018-09-10
MX365886B true MX365886B (es) 2019-06-19

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.

Country Status (8)

Country Link
US (1) US10285963B2 (OSRAM)
JP (1) JP2019521184A (OSRAM)
CN (1) CN109890369B (OSRAM)
BR (1) BR112018075395A2 (OSRAM)
CA (1) CA3027048A1 (OSRAM)
ES (1) ES2988151T3 (OSRAM)
MX (1) MX365886B (OSRAM)
RU (1) RU2749950C2 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017213486A2 (es) * 2016-06-08 2017-12-14 Astudillo De La Vega Horacio Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
WO2008143182A1 (ja) * 2007-05-17 2008-11-27 Kaneka Corporation 甘草ポリフェノールを含有する組成物
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Also Published As

Publication number Publication date
MX2017007448A (es) 2018-09-10
US10285963B2 (en) 2019-05-14
RU2749950C2 (ru) 2021-06-21
RU2018147077A (ru) 2020-07-10
CN109890369A (zh) 2019-06-14
BR112018075395A2 (pt) 2019-04-02
US20160354331A1 (en) 2016-12-08
CN109890369B (zh) 2022-04-29
RU2018147077A3 (OSRAM) 2020-09-21
JP2019521184A (ja) 2019-07-25
CA3027048A1 (en) 2017-12-14
ES2988151T3 (es) 2024-11-19

Similar Documents

Publication Publication Date Title
Chang et al. SIRT5‐related Desuccinylation modification contributes to quercetin‐induced protection against heart failure and high‐glucose‐prompted cardiomyocytes injured through regulation of mitochondrial quality surveillance
Jiang et al. Butyrate improves cardiac function and sympathetic neural remodeling following myocardial infarction in rats
Börgeson et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease
Sun et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity
Argilés et al. Muscle wasting in cancer: the role of mitochondria
GT201600263A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
Juvet et al. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning
Liu et al. Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats
CO6410287A2 (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
Mabhida et al. Protective effect of triterpenes against diabetes-induced β-cell damage: An overview of in vitro and in vivo studies
Wang et al. An update on AMPK in hydrogen sulfide pharmacology
WO2011057249A3 (en) Treatment of heart disease
NZ743706A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2011057251A3 (en) Treatment of heart disease
Wang et al. MicroRNA-134 contributes to glucose-induced endothelial cell dysfunction and this effect can be reversed by far-infrared irradiation
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
BR112012026907A2 (pt) método para a preparação de uma microvesícula suportando tf tendo atividade pró-coagulante, microvesículas obstidas pelo dito metodo e seu uso, bem como composição farmacêutica e kit as compreendendo
AR103371A1 (es) Composiciones y métodos para diagnosis y tratamiento de síndrome metabólico, uso
Basak et al. The interplay between glucose and fatty acids on tube formation and fatty acid uptake in the first trimester trophoblast cells, HTR8/SVneo
Mittal et al. Molecular mechanisms and epigenetic regulation in diabetic cardiomyopathy
CAI The oxidative stress and diabetic complications
Lv et al. Venlafaxine protects methylglyoxal-induced apoptosis in the cultured human brain microvascular endothelial cells
WO2015076717A3 (en) Mscs in the treatment of cardiac disorders
MX2017007448A (es) Combinacion de reguladores metabolicos bioenergeticos y nutra-epigeneticos, compuestos nutraceuticos en combinaciones convencionales y nanotecnologicas para revertir y prevenir la senescencia celular acelerada por daño cronico producida por diabetes y otras enfermedades complejas cronico-degenerativas.
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.

Legal Events

Date Code Title Description
FG Grant or registration